[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354042-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354042-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pik3ca-mutant-cervical-cancer-is-selectively-suppressed-by-pi3k-inhibition-alpelisibbyl-719-and-inavolisibgdc-0077-and-cooperates-with-hpv-directed-t-cell-therapy","PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy","","Cervical cancer is driven by human papillomavirus (HPV) infection, yet actionable molecular subtypes and targeted therapies are limited. The study defines three biologically and clinically relevant subtypes using public datasets and functional immune assays, highlighting worse survival with YAP1 amplification. PI3Kα inhibitors Alpelisib and Inavolisib selectively suppress proliferation in PIK3CA-mutant cervical cancer models, reducing HPV16 E7 and immune checkpoints. Combining PI3K inhibition with antigen-specific T-cell therapy enhances tumor killing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pik3ca-mutant-cervical-cancer-is-selectively-suppressed-by-pi3k-inhibition-alpelisibbyl-719-and-inavolisibgdc-0077-and-cooperates-with-hpv-directed-t-cell-therapy/354042/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pik3ca-mutant-cervical-cancer-is-selectively-suppressed-by-pi3k-inhibition-alpelisibbyl-719-and-inavolisibgdc-0077-and-cooperates-with-hpv-directed-t-cell-therapy/354042.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecular subtypes of cervical cancer were identified in the study?","Question",{"text":63,"@type":64},"The analysis defined three subtypes based on PIK3CA status and YAP1 amplification: PIK3CA wild-type without YAP1 amplification, PIK3CA-mutant without YAP1 amplification, and PIK3CA wild-type with YAP1 amplification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do PI3Kα inhibitors affect PIK3CA-mutant versus PIK3CA-wild-type cancer cells?",{"text":68,"@type":64},"Alpelisib (BYL-719) and Inavolisib (GDC-0077) selectively inhibited proliferation in multiple PIK3CA-mutant cervical cancer cell lines with minimal effects in PIK3CA wild-type cells.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is combining PI3K inhibition with HPV-directed T-cell therapy proposed?",{"text":72,"@type":64},"The combination enhanced tumor cell killing, with maximal effects observed when drug pretreatment occurred before T-cell exposure, supporting a synergistic strategy to improve outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354042,1790343481,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Neoplasia 76 (2026) 101305  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy |  | |\n| --- | --- | --- |\n| Hong Lou a, David Langan b, Nick Syracuse c , Elisabeth A. Murphy d, Sojung Kim b, Emma Robinson a, Nicole M. Rossic, Yi Xiec , Sonam Tulsyanc , Tawnjerae Joe c, Isabel Rodriguez c, Nina Raoc, Matthew R. Oberleyd, Mathias Oelkeb, Michael Dean c,* \u003Cbr>a Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD USA b NexImmune, Gaithersburg, MD USA\u003Cbr>c Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA d Caris Life Sciences, Phoenix, AZ, USA |  |  |\n| A R T I C L E I N F O\u003Cbr>Keywords:\u003Cbr>Cervical cancer, Immunotherapy, Immune checkpoint inhibitor, Major histocompatibility complex\u003Cbr>MHC, Virology, Real-world data, Clinical outcomes | A B S T R A C T\u003Cbr>Cervical cancer is largely driven by human papillomavirus (HPV) infection, yet clinically actionable molecular subtypes and effective targeted therapies remain limited. Here, we define biologically and clinically relevant subtypes and evaluate targeted therapeutic strategies. Analysis of public datasets, coupled with functional studies in cervical cancer cell lines and immune assays, identified three subtypes: (I) PIK3CA wild-type without YAP1 amplification,(II) PIK3CA-mutant without YAP1 amplification, and (III) PIK3CA wild-type with YAP1 amplification. Notably, YAP1 amplification is associated with poorer patient survival. The PI3Kα-specific inhibitors, Alpelisib (BYL-719) and Inavolisib (GDC-0077), selectively inhibited proliferation in multiple PIK3CA-mutant cervical cancer cell lines but had minimal effect in PIK3CA wild-type cells. Alpelisib further reduced expression of HPV16 E7, PD-L1 (CD274), YAP1, and EGFR specifically in PI3Kα-mutant models. In an HPV16-positive, HLAA2-positive, PIK3CA-mutant cell line (CaSki), antigen-specific donor T cells (NexImmune) induced cytotoxicity ina dose-dependent manner. Importantly, combining BYL-719 with T-cell therapy enhanced tumor cell killing, with maximal effects observed following drug pretreatment prior to T-cell exposure. These findings identify actionable molecular subtypes of cervical cancer and support targeting PI3Kα in PIK3CA-mutant tumors. Moreover, combining PI3K inhibition with antigen-specific immunotherapy represents a promising strategy to improve outcomes in advanced HPV16-associated cervical cancer. |  |\n\nIntroduction  \nCervical cancer (CC) is the most common tumor driven by human papillomavirus (HPV). While most infected individuals spontaneously clear HPV, persistent infections of high-risk (HR) HPV types in cervical tissue can lead to cervical intraepithelial neoplasia (CIN), the precursor to CC. The estimated global annual impact of CC is as high as 569,847 new cases and 311,365 deaths [1]. More than half of CC development is associated with the highly oncogenic HPV16, and the predominant histologic subtype of invasive carcinoma is squamous cell carcinoma (SCC), accounting for about 75% of cases.  \nHPV is a foreign pathogen expressing antigens within host cells, and  \nthe immune system frequently recognizes and eliminates infected cells. However, the virus has evolved mechanisms to evade the immune system, including upregulating CD274 (PD-L1) and CTLA-4 and silencing the expression of most viral proteins in tumor cells. Immune escape is also crucial for cancer survival and metastasis [2]. Specifically, PD-L1 is overexpressed in virally induced cancers. There are high levels of PD-L1 in approximately 95% of cervical","cbCain6I3fibA6Ay","https://ap.wps.com/l/cbCain6I3fibA6Ay","pdf",3081682,"English","# Introduction\n# Materials and Methods\n# Results\n# Discussion","[{\"question\":\"What molecular subtypes of cervical cancer were identified in the study?\",\"answer\":\"The analysis defined three subtypes based on PIK3CA status and YAP1 amplification: PIK3CA wild-type without YAP1 amplification, PIK3CA-mutant without YAP1 amplification, and PIK3CA wild-type with YAP1 amplification.\"},{\"question\":\"How do PI3Kα inhibitors affect PIK3CA-mutant versus PIK3CA-wild-type cancer cells?\",\"answer\":\"Alpelisib (BYL-719) and Inavolisib (GDC-0077) selectively inhibited proliferation in multiple PIK3CA-mutant cervical cancer cell lines with minimal effects in PIK3CA wild-type cells.\"},{\"question\":\"Why is combining PI3K inhibition with HPV-directed T-cell therapy proposed?\",\"answer\":\"The combination enhanced tumor cell killing, with maximal effects observed when drug pretreatment occurred before T-cell exposure, supporting a synergistic strategy to improve outcomes.\"}]","PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy | PDF",1790108555,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c330914686f6335efc0aa8e341306d68.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14eaadd97b8e4d0dfc25a50508a7141f.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d10900860690baa598c8358076739c6.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37747b85b28b1428b370d4de1c078c60.webp",980,1306]